Cambridge Investment Research Advisors, Inc. Castle Biosciences Inc Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 9,102 shares of CSTL stock, worth $172,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,102
Previous 9,102
-0.0%
Holding current value
$172,300
Previous $260,000
6.54%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CSTL
# of Institutions
210Shares Held
26.6MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$57.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$34.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$34 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$27.2 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$18.9 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $498M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...